ArticleScientific reports2025
Identification of TSEN15 as a novel biomarker for diagnosis, prognosis, and immune infiltration in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
TRNA splicing endonuclease subunit 15 (TSEN15) is known for its role in cell cycle regulation, but its involvement in hepatocellular carcinoma (HCC) remains underexplored. TSEN15 influences mitosis and cancer cell proliferation. Its effects on immune infiltration and prognostic value in HCC demand further study. HCC patient data were analyzed using The Cancer Genome Atlas (TCGA). TSEN15 expression in HCC tissues was significantly higher than in normal liver tissues. High TSEN15 levels were associated with advanced HCC stages, such as T3, T4, and M1. Survival analyses showed TSEN15 as an independent negative prognostic marker for overall survival. Immune profiling revealed that elevated TSEN15 expression correlates with reduced infiltration of cytotoxic immune cells, including CD8 + T cells, NK cells, and dendritic cells. Functional enrichment analyses linked TSEN15 to pathways promoting tumor progression. Results were validated through Western blotting, RT-qPCR, and cellular assays. TSEN15 serves as a novel biomarker for HCC diagnosis and prognosis, indicating its potential as a target for therapeutic interventions. Its role in promoting tumor proliferation, modulating immune infiltration, and influencing clinical outcomes underscores its clinical significance in HCC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.